메뉴 건너뛰기




Volumn 25, Issue 3, 2014, Pages 249-259

Beyond angiogenesis blockade: Targeted therapy for advanced cervical cancer

Author keywords

Angiogenesis; Recurrent cervical cancer; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FOLIC ACID ANTAGONIST; GEFITINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATUZUMAB; MK 1775; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOTCH RECEPTOR; OLAPARIB; PD 0166285; PEMETREXED; TEMSIROLIMUS; UNCLASSIFIED DRUG; VALPROIC ACID; VELIPARIB;

EID: 84904670005     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2014.25.3.249     Document Type: Review
Times cited : (35)

References (71)
  • 3
    • 84873527086 scopus 로고    scopus 로고
    • Treatment of metastatic cervical cancer: Future directions involving targeted agents
    • Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A. Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol 2013;85:303-14
    • (2013) Crit Rev Oncol Hematol , vol.85 , pp. 303-314
    • Diaz-Padilla, I.1    Monk, B.J.2    Mackay, H.J.3    Oaknin, A.4
  • 5
    • 0019408691 scopus 로고
    • Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group
    • Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981;48:899-903.
    • (1981) Cancer , vol.48 , pp. 899-903
    • Thigpen, T.1    Shingleton, H.2    Homesley, H.3    Lagasse, L.4    Blessing, J.5
  • 6
    • 0024747607 scopus 로고
    • A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study
    • McGuire WP 3rd, Arseneau J, Blessing JA, DiSaia PJ, Hatch KD, Given FT Jr, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:1462-8.
    • (1989) J Clin Oncol , vol.7 , pp. 1462-1468
    • McGuire III., W.P.1    Arseneau, J.2    Blessing, J.A.3    Disaia, P.J.4    Hatch, K.D.5    Given Jr., F.T.6
  • 7
    • 0037486920 scopus 로고    scopus 로고
    • Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: A gynecologic oncology group study
    • Fracasso PM, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2003;90:177-80.
    • (2003) Gynecol Oncol , vol.90 , pp. 177-180
    • Fracasso, P.M.1    Blessing, J.A.2    Wolf, J.3    Rocereto, T.F.4    Berek, J.S.5    Waggoner, S.6
  • 8
    • 0029041394 scopus 로고
    • Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: A Gynecologic Oncology Group study
    • Thigpen T, Blessing JA, Gallup DG, Maiman M, Soper JT. Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1995;57:376-9.
    • (1995) Gynecol Oncol , vol.57 , pp. 376-379
    • Thigpen, T.1    Blessing, J.A.2    Gallup, D.G.3    Maiman, M.4    Soper, J.T.5
  • 9
    • 0024450677 scopus 로고
    • Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: A Gynecologic Oncology Group study
    • Sutton GP, Blessing JA, Adcock L, Webster KD, DeEulis T. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs 1989;7:341-3.
    • (1989) Invest New Drugs , vol.7 , pp. 341-343
    • Sutton, G.P.1    Blessing, J.A.2    Adcock, L.3    Webster, K.D.4    Deeulis, T.5
  • 10
    • 0032168956 scopus 로고    scopus 로고
    • A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: A gynecologic oncology group study
    • Look KY, Blessing JA, Levenback C, Kohler M, Chafe W, Roman LD. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 1998;70:334-8.
    • (1998) Gynecol Oncol , vol.70 , pp. 334-338
    • Look, K.Y.1    Blessing, J.A.2    Levenback, C.3    Kohler, M.4    Chafe, W.5    Roman, L.D.6
  • 11
    • 0033959650 scopus 로고    scopus 로고
    • Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A Phase II study of the gynecologic oncology group
    • Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol 2000;76:204-7.
    • (2000) Gynecol Oncol , vol.76 , pp. 204-207
    • Schilder, R.J.1    Blessing, J.A.2    Morgan, M.3    Mangan, C.E.4    Rader, J.S.5
  • 12
    • 0034089496 scopus 로고    scopus 로고
    • Topotecan in squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group
    • Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000;77:446-9.
    • (2000) Gynecol Oncol , vol.77 , pp. 446-449
    • Bookman, M.A.1    Blessing, J.A.2    Hanjani, P.3    Herzog, T.J.4    Andersen, W.A.5
  • 13
    • 0035281646 scopus 로고    scopus 로고
    • Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study
    • Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001;19:1275-8.
    • (2001) J Clin Oncol , vol.19 , pp. 1275-1278
    • Curtin, J.P.1    Blessing, J.A.2    Webster, K.D.3    Rose, P.G.4    Mayer, A.R.5    Fowler Jr., W.C.6
  • 14
    • 0029865737 scopus 로고    scopus 로고
    • Paclitaxel has moderate activity in squamous cervix cancer: A Gynecologic Oncology Group study
    • McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 1996;14:792-5.
    • (1996) J Clin Oncol , vol.14 , pp. 792-795
    • McGuire, W.P.1    Blessing, J.A.2    Moore, D.3    Lentz, S.S.4    Photopulos, G.5
  • 15
    • 34548437625 scopus 로고    scopus 로고
    • Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
    • Gynecologic Oncology Group Study
    • Garcia AA, Blessing JA, Vaccarello L, Roman LD; Gynecologic Oncology Group Study. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol 2007;30:428-31.
    • (2007) Am J Clin Oncol , vol.30 , pp. 428-431
    • Garcia, A.A.1    Blessing, J.A.2    Vaccarello, L.3    Roman, L.D.4
  • 16
    • 10044278053 scopus 로고    scopus 로고
    • Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: A Gynecologic Oncology Group Study
    • Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2005;96:108-11.
    • (2005) Gynecol Oncol , vol.96 , pp. 108-111
    • Muggia, F.M.1    Blessing, J.A.2    Waggoner, S.3    Berek, J.S.4    Monk, B.J.5    Sorosky, J.6
  • 17
    • 0036534291 scopus 로고    scopus 로고
    • Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: A gynecologic oncology group study
    • Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2002;20:1832-7.
    • (2002) J Clin Oncol , vol.20 , pp. 1832-1837
    • Bloss, J.D.1    Blessing, J.A.2    Behrens, B.C.3    Mannel, R.S.4    Rader, J.S.5    Sood, A.K.6
  • 18
    • 23044495279 scopus 로고    scopus 로고
    • Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study
    • Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-33.
    • (2005) J Clin Oncol , vol.23 , pp. 4626-4633
    • Long III., H.J.1    Bundy, B.N.2    Grendys Jr., E.C.3    Benda, J.A.4    McMeekin, D.S.5    Sorosky, J.6
  • 19
    • 70350433286 scopus 로고    scopus 로고
    • Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study
    • Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
    • (2009) J Clin Oncol , vol.27 , pp. 4649-4655
    • Monk, B.J.1    Sill, M.W.2    McMeekin, D.S.3    Cohn, D.E.4    Ramondetta, L.M.5    Boardman, C.H.6
  • 20
    • 4143135504 scopus 로고    scopus 로고
    • Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study
    • Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113-9.
    • (2004) J Clin Oncol , vol.22 , pp. 3113-3119
    • Moore, D.H.1    Blessing, J.A.2    McQuellon, R.P.3    Thaler, H.T.4    Cella, D.5    Benda, J.6
  • 21
    • 0031023552 scopus 로고    scopus 로고
    • Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study
    • Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997;15:165-71.
    • (1997) J Clin Oncol , vol.15 , pp. 165-171
    • Omura, G.A.1    Blessing, J.A.2    Vaccarello, L.3    Berman, M.L.4    Clarke-Pearson, D.L.5    Mutch, D.G.6
  • 23
    • 31444440292 scopus 로고    scopus 로고
    • Nuclear EGFR signalling network in cancers: Linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival
    • Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006;94:184-8.
    • (2006) Br J Cancer , vol.94 , pp. 184-188
    • Lo, H.W.1    Hung, M.C.2
  • 24
    • 0033966576 scopus 로고    scopus 로고
    • In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
    • Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-8.
    • (2000) Clin Cancer Res , vol.6 , pp. 701-708
    • Milas, L.1    Mason, K.2    Hunter, N.3    Petersen, S.4    Yamakawa, M.5    Ang, K.6
  • 25
    • 0034084314 scopus 로고    scopus 로고
    • Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
    • Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74.
    • (2000) Clin Cancer Res , vol.6 , pp. 2166-2174
    • Huang, S.M.1    Harari, P.M.2
  • 26
    • 0033748391 scopus 로고    scopus 로고
    • Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide
    • Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000;6:4343-50.
    • (2000) Clin Cancer Res , vol.6 , pp. 4343-4350
    • Bianco, C.1    Bianco, R.2    Tortora, G.3    Damiano, V.4    Guerrieri, P.5    Montemaggi, P.6
  • 27
    • 0032719534 scopus 로고    scopus 로고
    • Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
    • Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-90.
    • (1999) Clin Cancer Res , vol.5 , pp. 2884-2890
    • Akimoto, T.1    Hunter, N.R.2    Buchmiller, L.3    Mason, K.4    Ang, K.K.5    Milas, L.6
  • 30
    • 80051551247 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
    • Santin AD, Sill MW, McMeekin DS, Leitao MM Jr, Brown J, Sutton GP, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2011;122:495-500.
    • (2011) Gynecol Oncol , vol.122 , pp. 495-500
    • Santin, A.D.1    Sill, M.W.2    McMeekin, D.S.3    Leitao Jr., M.M.4    Brown, J.5    Sutton, G.P.6
  • 32
    • 79955481029 scopus 로고    scopus 로고
    • Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study
    • Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 2011;121:303-8.
    • (2011) Gynecol Oncol , vol.121 , pp. 303-308
    • Farley, J.1    Sill, M.W.2    Birrer, M.3    Walker, J.4    Schilder, R.J.5    Thigpen, J.T.6
  • 34
    • 37449004176 scopus 로고    scopus 로고
    • A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
    • Goncalves A, Fabbro M, Lhomme C, Gladieff L, Extra JM, Floquet A, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008;108:42-6.
    • (2008) Gynecol Oncol , vol.108 , pp. 42-46
    • Goncalves, A.1    Fabbro, M.2    Lhomme, C.3    Gladieff, L.4    Extra, J.M.5    Floquet, A.6
  • 35
    • 58149151263 scopus 로고    scopus 로고
    • Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer
    • Nogueira-Rodrigues A, do Carmo CC, Viegas C, Erlich F, Camisao C, Fontao K, et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res 2008;14:6324-9.
    • (2008) Clin Cancer Res , vol.14 , pp. 6324-6329
    • Nogueira-Rodrigues, A.1    do Carmo, C.C.2    Viegas, C.3    Erlich, F.4    Camisao, C.5    Fontao, K.6
  • 36
    • 69449086850 scopus 로고    scopus 로고
    • A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
    • Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009;19:929-33.
    • (2009) Int J Gynecol Cancer , vol.19 , pp. 929-933
    • Schilder, R.J.1    Sill, M.W.2    Lee, Y.C.3    Mannel, R.4
  • 37
    • 77955874058 scopus 로고    scopus 로고
    • Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer
    • Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-9.
    • (2010) J Clin Oncol , vol.28 , pp. 3562-3569
    • Monk, B.J.1    Mas, L.L.2    Zarba, J.J.3    Oaknin, A.4    Tarpin, C.5    Termrungruanglert, W.6
  • 38
    • 27144469023 scopus 로고    scopus 로고
    • Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix
    • Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005;99:415-21.
    • (2005) Gynecol Oncol , vol.99 , pp. 415-421
    • Lee, C.M.1    Shrieve, D.C.2    Zempolich, K.A.3    Lee, R.J.4    Hammond, E.5    Handrahan, D.L.6
  • 40
    • 0036527775 scopus 로고    scopus 로고
    • Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
    • Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
    • (2002) Nat Rev Drug Discov , vol.1 , pp. 287-299
    • Johnstone, R.W.1
  • 41
    • 30344477367 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
    • Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
    • (2006) Nat Rev Cancer , vol.6 , pp. 38-51
    • Minucci, S.1    Pelicci, P.G.2
  • 42
    • 34447304130 scopus 로고    scopus 로고
    • Valproic acid (VPA) in patients with refractory advanced cancer: A dose escalating phase I clinical trial
    • Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007;97:177-82.
    • (2007) Br J Cancer , vol.97 , pp. 177-182
    • Atmaca, A.1    Al-Batran, S.E.2    Maurer, A.3    Neumann, A.4    Heinzel, T.5    Hentsch, B.6
  • 43
    • 26844505068 scopus 로고    scopus 로고
    • Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer: A phase I study
    • Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja- Chayeb L, Cetina L, Candelaria M, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer: a phase I study. Mol Cancer 2005;4:22.
    • (2005) Mol Cancer , vol.4 , pp. 22
    • Chavez-Blanco, A.1    Segura-Pacheco, B.2    Perez-Cardenas, E.3    Taja-Chayeb, L.4    Cetina, L.5    Candelaria, M.6
  • 44
    • 84655175030 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer: Preliminary results
    • Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonzalez-Fierro A, de la Cruz-Hernandez E, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer: preliminary results. Med Oncol 2011;28 Suppl 1:S540-6.
    • (2011) Med Oncol , vol.28 , Issue.SUPPL. 1
    • Coronel, J.1    Cetina, L.2    Pacheco, I.3    Trejo-Becerril, C.4    Gonzalez-Fierro, A.5    de la Cruz-Hernandez, E.6
  • 46
    • 0036632368 scopus 로고    scopus 로고
    • The phosphatidylinositol 3-Kinase AKT pathway in human cancer
    • Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
    • (2002) Nat Rev Cancer , vol.2 , pp. 489-501
    • Vivanco, I.1    Sawyers, C.L.2
  • 47
    • 84861690519 scopus 로고    scopus 로고
    • Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
    • Diaz-Padilla I, Duran I, Clarke BA, Oza AM. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat Rev 2012;38:767-75.
    • (2012) Cancer Treat Rev , vol.38 , pp. 767-775
    • Diaz-Padilla, I.1    Duran, I.2    Clarke, B.A.3    Oza, A.M.4
  • 48
    • 38149108890 scopus 로고    scopus 로고
    • All roads lead to mTOR: Integrating inflammation and tumor angiogenesis
    • Lee DF, Hung MC. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 2007;6:3011-4.
    • (2007) Cell Cycle , vol.6 , pp. 3011-3014
    • Lee, D.F.1    Hung, M.C.2
  • 49
    • 70349741010 scopus 로고    scopus 로고
    • Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin
    • Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009;69:7311-9.
    • (2009) Cancer Res , vol.69 , pp. 7311-7319
    • Liu, D.1    Hou, P.2    Liu, Z.3    Wu, G.4    Xing, M.5
  • 50
    • 68249093818 scopus 로고    scopus 로고
    • Targeting the phosphoinositide 3-kinase pathway in cancer
    • Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
    • (2009) Nat Rev Drug Discov , Issue.8 , pp. 627-644
    • Liu, P.1    Cheng, H.2    Roberts, T.M.3    Zhao, J.J.4
  • 51
    • 77953711939 scopus 로고    scopus 로고
    • MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
    • Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-22.
    • (2010) Cancer Biol Ther , vol.9 , pp. 514-522
    • Hirai, H.1    Arai, T.2    Okada, M.3    Nishibata, T.4    Kobayashi, M.5    Sakai, N.6
  • 52
    • 0042698478 scopus 로고    scopus 로고
    • Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function
    • Dixon H, Norbury CJ. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 2002;1:362-8.
    • (2002) Cell Cycle , vol.1 , pp. 362-368
    • Dixon, H.1    Norbury, C.J.2
  • 53
    • 16544392882 scopus 로고    scopus 로고
    • Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis
    • Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004;3:305-13.
    • (2004) Cancer Biol Ther , vol.3 , pp. 305-313
    • Wang, Y.1    Decker, S.J.2    Sebolt-Leopold, J.3
  • 55
    • 78951481235 scopus 로고    scopus 로고
    • Role of Notch and its oncogenic signaling crosstalk in breast cancer
    • Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 2011; 1815:197-213.
    • (2011) Biochim Biophys Acta , vol.1815 , pp. 197-213
    • Guo, S.1    Liu, M.2    Gonzalez-Perez, R.R.3
  • 56
    • 67650660754 scopus 로고    scopus 로고
    • The Notch signaling pathway: Transcriptional regulation at Notch target genes
    • Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009;66:1631-46.
    • (2009) Cell Mol Life Sci , vol.66 , pp. 1631-1646
    • Borggrefe, T.1    Oswald, F.2
  • 57
    • 0032242705 scopus 로고    scopus 로고
    • Notch signalling and the control of cell fate choices in vertebrates
    • Lewis J. Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 1998;9:583-9.
    • (1998) Semin Cell Dev Biol , vol.9 , pp. 583-589
    • Lewis, J.1
  • 58
    • 0032574857 scopus 로고    scopus 로고
    • Notch signalling: A short cut to the nucleus
    • Lewis J. Notch signalling: a short cut to the nucleus. Nature 1998; 393:304-5.
    • (1998) Nature , vol.393 , pp. 304-305
    • Lewis, J.1
  • 59
    • 0029065486 scopus 로고
    • Developmental genetics: The Notch connection
    • Simpson P. Developmental genetics: the Notch connection. Nature 1995;375:736-7
    • (1995) Nature , vol.375 , pp. 736-737
    • Simpson, P.1
  • 60
    • 0030927183 scopus 로고    scopus 로고
    • The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions
    • Daniel B, Rangarajan A, Mukherjee G, Vallikad E, Krishna S. The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions. J Gen Virol 1997;78:1095-101.
    • (1997) J Gen Virol , vol.78 , pp. 1095-1101
    • Daniel, B.1    Rangarajan, A.2    Mukherjee, G.3    Vallikad, E.4    Krishna, S.5
  • 62
    • 50849117455 scopus 로고    scopus 로고
    • The role of Notch signaling in human cervical cancer: Implications for solid tumors
    • Maliekal TT, Bajaj J, Giri V, Subramanyam D, Krishna S. The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene 2008;27:5110-4.
    • (2008) Oncogene , vol.27 , pp. 5110-5114
    • Maliekal, T.T.1    Bajaj, J.2    Giri, V.3    Subramanyam, D.4    Krishna, S.5
  • 63
    • 64949083563 scopus 로고    scopus 로고
    • Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90
    • Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 2009;29:797-807.
    • (2009) Anticancer Res , vol.29 , pp. 797-807
    • Koga, F.1    Kihara, K.2    Neckers, L.3
  • 64
    • 21744445069 scopus 로고    scopus 로고
    • Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications
    • Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86-103.
    • (2005) Cell Stress Chaperones , vol.10 , pp. 86-103
    • Ciocca, D.R.1    Calderwood, S.K.2
  • 65
    • 67651149741 scopus 로고    scopus 로고
    • Expression of heat shock protein 60 kDa is upregulated in cervical cancer
    • Hwang YJ, Lee SP, Kim SY, Choi YH, Kim MJ, Lee CH, et al. Expression of heat shock protein 60 kDa is upregulated in cervical cancer. Yonsei Med J 2009;50:399-406.
    • (2009) Yonsei Med J , vol.50 , pp. 399-406
    • Hwang, Y.J.1    Lee, S.P.2    Kim, S.Y.3    Choi, Y.H.4    Kim, M.J.5    Lee, C.H.6
  • 66
    • 77955348541 scopus 로고    scopus 로고
    • Hsp90 as a gatekeeper of tumor angiogenesis: Clinical promise and potential pitfalls
    • Bohonowych JE, Gopal U, Isaacs JS. Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol 2010; 2010:412985.
    • (2010) J Oncol , pp. 412985
    • Bohonowych, J.E.1    Gopal, U.2    Isaacs, J.S.3
  • 67
    • 0031826984 scopus 로고    scopus 로고
    • Expression of heat shock protein 70 and c-myc in cervical carcinoma
    • Abd el All H, Rey A, Duvillard P. Expression of heat shock protein 70 and c-myc in cervical carcinoma. Anticancer Res 1998;18(3A):1533-6.
    • (1998) Anticancer Res , vol.18 , Issue.3 A , pp. 1533-1536
    • el Abd, A.H.1    Rey, A.2    Duvillard, P.3
  • 68
    • 9144261127 scopus 로고    scopus 로고
    • Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity
    • Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003;63:8984-95.
    • (2003) Cancer Res , vol.63 , pp. 8984-8995
    • Bisht, K.S.1    Bradbury, C.M.2    Mattson, D.3    Kaushal, A.4    Sowers, A.5    Markovina, S.6
  • 69
    • 84891068902 scopus 로고    scopus 로고
    • The role of PARP inhibitors in the treatment of gynecologic malignancies
    • Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol 2013;3:237.
    • (2013) Front Oncol , vol.3 , pp. 237
    • Reinbolt, R.E.1    Hays, J.L.2
  • 70
    • 84866911186 scopus 로고    scopus 로고
    • Present status and problems on molecular targeted therapy of cancer
    • Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012;44:1-10.
    • (2012) Cancer Res Treat , vol.44 , pp. 1-10
    • Saijo, N.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.